Niznik Leads Study That Identifies Benefits of De-prescribing AChEls

Assistant professor Joshua Niznik, PhD, PharmD, in the division of Geriatric Medicine, published a study in the Journal of the American Geriatrics Society that suggests de-prescribing Acetylcholinesterase Inhibitors (AChEls) as a reasonable approach to lowering polypharmacy.

Niznik Leads Study That Identifies Benefits of De-prescribing AChEls click to enlarge Joshua Niznik, PhD, PharmD

The study also says de-prescribing AChEIs can lower risk of serious falls or fractures without increasing risk for all-cause negative events in nursing home residents with severe dementia. 

Co-authors include Laura Hanson, MD, MPH, Division of Geriatric Medicine, Carolyn Thorpe, PhD, MPH, Eshelman School of Pharmacy, Division of Pharmaceutical Outcomes and Policy, and Josh Thorpe, PhD, MPH, Eshelman School of Pharmacy, Division of Pharmaceutical Outcomes and Policy.

Filed under: